Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis

Emery, Paul; Fleischmann, Roy M.; Moreland, Larry W.; Hsia, Elizabeth C.; Strusberg, Ingrid; Durez, Patrick; Nash, Peter; Amante, Eric Jason B.; Churchill, Melvin; Park, Won; Pons-Estel, Bernardo Antonio; Doyle, Mittie K.; Visvanathan, Sudha; Xu, Weichun; Rahman, Mahboob U.

Published in

Wiley, Arthritis and Rheumatism, 8(60), p. 2272-2283, 2009

DOI: 10.1002/art.24638

Tools

Export citation

Search in Google Scholar

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis

Journal article published in 2009 by Paul Emery, Roy M. Fleischmann, Larry W. Moreland, Elizabeth C. Hsia, Ingrid Strusberg, Patrick Durez, Peter Nash

, Eric Jason B. Amante, Melvin Churchill, Won Park, Bernardo Antonio Pons-Estel, Mittie K. Doyle, Sudha Visvanathan, Weichun Xu, Mahboob U. Rahman

This paper is available in a repository.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools